A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT06720987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations
Study identification
- NCT ID
- NCT06720987
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Interventions
- Cetuximab Drug
- KQB198 Drug
- KQB365 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2025
- Primary completion
- Jun 29, 2029
- Completion
- Jun 29, 2030
- Last update posted
- Apr 22, 2026
2025 – 2030
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic, Phoenix | Phoenix | Arizona | 85054 | Recruiting |
| Sarah Cannon Cancer Institute at HealthONE | Denver | Colorado | 80218 | Recruiting |
| Mayo Clinic, Jacksonville | Jacksonville | Florida | 32224 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Mayo Clinic, Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Cleveland Clinic, Taussig Cancer Institute | Cleveland | Ohio | 44195 | Recruiting |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Sydney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| NEXT Virginia, LLC | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06720987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06720987 live on ClinicalTrials.gov.